Previous reports attempting to evaluate the clinical efficacy of intravesical bacillus Calmette-Guérin (BCG) therapy in patients taking fibrin clot inhibitors (FCI) have yielded conflicting results and are primarily based on patient cohorts treated with only induction BCG.
Briana Walton: My name is Briana Walton. I am a female pelvic medicine and reconstructive surgeon out of the University of Maryland. And I have to admit, I feel a little bit out of place here, but my background is also not just medicine. I also have a degree in art and design. So one […]
Steven Kaplan: We’ll talk a little about some new therapies in BPH, and I figured I’d have a hot seat in there. These are my disclosures, I’m the PI for both the Urotronic and proverum device, which I’ll talk about in just a couple of moments. This is going to be a relatively quick talk, because […]
Michael O’Donnell: So today, we’re going to talk about intravesical therapies for non-muscle invasive disease. And like Noah, it’s hard to cover all this in 15 minutes, but I think I can give you a good taste of everything. These are my disclosures. Nothing particularly relevant, relative to today’s discussion. There are several indications for […]
Active Surveillance Background Prostate cancer represents a public health dilemma: while prostate cancer is the second leading cause of death among men in the US1 and third in Canada,2 it is widely over-diagnosed and over-treated, leading to significant patient anxiety and morbidity.3 Much of the over-diagnosis of prostate cancer relates to the use of serum prostate-specific antigen […]
Over the nearly two years of navigating the COVID pandemic, urology practices were forced to increase their efficiency by focusing on streamlining patient visits without sacrificing care quality. However, postponed checkups were unavoidable as the public was encouraged to stay home. According to the Centers for Disease Control and Prevention (CDC), 40% of Americans in […]
James Wysock: Thanks Dr. Shore. So this is the hot seat presentation. I’m James Wysock from NYU. And I just want to say, thanks for having me here. What we’re going to talk about is a little bit about imaging of the prostate high and low frequency ultrasound versus MRI, and to try to keep […]
Emmanuel Antonarakis: Thank you, Neal. I’ve been working in prostate cancer for 12 years, and this is my first time at a LUGPA meeting so, hopefully, it won’t be the last. I will be sharing the stage with my esteemed colleagues, doctors Fabrizio, Morris, and Hafron, and I’ll be beginning with some remarks for about […]
Phillip Kuo: Hello everyone. Thank you. And thank you to the meeting organizers for giving the opportunity for the Society of Nuclear Medicine, Molecular Imaging to speak at this great meeting. I’ve been given the task of this, I thought a pretty provocative title, Theranostics: Taking Over Cancer Care? And that is a question which […]
Steven Rowe: Thanks very much for the introduction. I look forward to this discussion. I wish I could be physically present with everyone, but still happy to be joining you from Baltimore. My topic today is PSMA Imaging: Is Conventional Imaging Obsolete? Probably. All right. That’s really all I have to say, thanks for your […]
